Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04886128 · ClinicalTrials.gov registry record
Improving Diagnostic Accuracy for Acute Heart Failure
A clinical trial of Dyspnea and Acute Heart Failure, sponsored by Vanderbilt University Medical Center.
- Active
- Registry status
- 2,800
- Enrollment target
- 1
- Study location
NCT04886128: Active study of Dyspnea and Acute Heart Failure, sponsored by Vanderbilt University Medical Center.
NCT04886128 is a study of Dyspnea and Acute Heart Failure that is active but no longer recruiting, run by Vanderbilt University Medical Center. The registered enrollment target is 2,800 participants, above the 184-participant average among 23 other Dyspnea trials with a reported enrollment target (1422% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04886128, a study of Dyspnea and Acute Heart Failure, is active but no longer recruiting, sponsored by Vanderbilt University Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- 2,800 participants
- Enrollment target
- 1
- Study location
Study Summary
Acute heart failure is a common reason for emergency department visits and hospitalization, but the diagnosis can be challenging because of non-specific symptoms and signs. The current diagnostic approach to acute heart failure has modest accuracy, leading to delayed diagnosis and treatment, which associate with worse prognosis. Prior work suggests diagnostic accuracy can be improved with the addition of multiple circulating biomarkers discovered through proteomics, and this study will derive and validate a multi-marker model to improve diagnostic accuracy for acute heart failure in the emergency department.
Primary Outcome
Define the multi-marker panel of 21 proteins that may improve diagnostic accuracy for acute heart failure
Conditions Studied
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,800 participants |
| Start Date | 2021-08-31 |
| Est. Completion | 2026-06-30 |
What the registry record for NCT04886128 still lists
NCT04886128 is an observational study that tracks outcomes without assigning an intervention. Its 2,800 participants enrollment target places it among the larger protocols in the corpus, above the 184-participant average among 23 other Dyspnea trials with a reported enrollment target (1422% higher).
The record links to 3 conditions, with Dyspnea appearing as the primary indexed condition, and to 0 interventions.
NCT04886128 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT04886128 about?
NCT04886128 is a clinical study titled "Improving Diagnostic Accuracy for Acute Heart Failure". Acute heart failure is a common reason for emergency department visits and hospitalization, but the diagnosis can be challenging because of non-specific symptoms and signs. The current diagnostic approach to acute heart failure has modest accuracy, leading to delayed diagnosis and treatment, which a...
What is the current status of trial NCT04886128?
This trial is currently active not recruiting. The enrollment target is 2,800 participants. The study started on 2021-08-31. Estimated completion is 2026-06-30.
What conditions does trial NCT04886128 study?
This clinical trial studies the following conditions: Dyspnea, Acute Heart Failure, Dyspnea; Cardiac.
Who is sponsoring clinical trial NCT04886128?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04886128 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dyspnea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04886128's enrollment target sits among peer trials
2,800 1st of 23 higher than 23 of 23 other Dyspnea trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dyspnea trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
129Xe MRI Cardiopulmonary
RECRUITING · Phase 2
-
Structured Personalized Oxygen and Supportive Therapies for Dyspnea in Oncology
RECRUITING · Phase 2
-
The Increase of Lung Capacity Using the Lung Master (Pulmonary Exerciser)
RECRUITING · NA
-
Ventilatory and Perfusion Abnormalities in Individuals With Post-Acute Sequelae of SARS-CoV-2 Infection
RECRUITING
-
Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH
RECRUITING · Phase 2
-
Inspiratory Muscle Training for Breast Cancer Patients on Chemotherapy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05443737 · 2,800 participants · Phase 3
Evaluation of a Telehealth Oncofertility Care Intervention in Adolescent and Young Adult Cancer Patients
- NCT05899439 · 2,800 participants
Immune Function and the Progression to T1D
- NCT06089109 · 2,800 participants · NA
Creating VIP Corps to Reduce Maternal Deaths
- NCT06345339 · 2,800 participants · Phase 2
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI